Dec 23, 2020
Dr. Ragen discusses X4 Pharmaceuticals, which is currently developing therapies for rare genetic diseases that result from dysfunction of the immune system and is currently undergoing a global Phase 3 trial for WHIM Syndrome and two Phase 1b trials for Waldenstrom macroglobulinemia (WM), a type of rare lymphoma, and severe congenital neutropenia (SCN).